You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Tempus is developing a new predictive bioinformatics model to improve clinical trial enrollment for Janssen, while the pharma firm has joined Tempus' TIME Trial.
Despite plenty of hype and some growing pains, artificial intelligence is starting to prove its value in academic and community cancer centers.
The company formerly known as TransMed Systems looks to bring "clarity and transparency" to the emerging field of precision oncology and in patient-trial matching.
The companies will develop analytics tools and leverage the Syapse Learning Health Network in an effort to shorten the time to market for new cancer therapies.
Symbolized by its first time exhibiting at HIMSS, Roche Diagnostics is using data to bridge the worlds of imaging, sequencing, diagnostics, drug discovery, and treatment.